The experimental drug- camlipixant, is at the heart of the deal, which is in late-stage development as a treatment for refractory chronic cough (RCC)
The experimental drug- camlipixant, is at the heart of the deal, which is in late-stage development as a treatment for refractory chronic cough (RCC) The experimental drug- camlipixant, is at the heart of the deal, which is in late-stage development as a treatment for refractory chronic cough (RCC) Moneycontrol Latest News Read More
